Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metastatic Kidney Cancer of Bad Prognosis

Trial Profile

Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metastatic Kidney Cancer of Bad Prognosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms POORTOR
  • Most Recent Events

    • 08 Jun 2014 Planned number of patients changed from 90 to 92 as reported by ClinicalTrials.gov.
    • 08 Jun 2014 Planned End Date changed from 1 Jan 2019 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 05 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top